http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-106093230-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2030-027 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N30-02 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N30-02 |
| filingDate | 2016-06-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2018-07-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2018-07-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-106093230-B |
| titleOfInvention | N in a kind of measurement blood plasma1The LC-MS-MS methods of methyl niacinamide concentration |
| abstract | The invention discloses N in a kind of measurement blood plasma 1 Methyl niacinamide (N 1 MNA 50 μ L of plasma sample are added in) the LC MS MS methods of concentration in 1.5mL plastic centrifuge tubes, and 30ngmL is added ‑1 20 μ L of internal standard N ' methyl niacinamide (N ' MNA) solution add 160 μ L acetonitriles, and vortex vibrates 2min, and Aspirate supernatant carries out LC MS MS analyses after centrifugation.The present invention establishes N 1 Assay methods of the MNA in human body, compared with the method for document report, this method pre-treatment is easier, and lower limit of quantitation is lower, and analysis time is shorter, less using plasma sample amount, to study N 1 MNA and fat, diabetes and coronary heart disease correlation, find new biomarker, improve clinical prevention and treatment level provides technical support. |
| priorityDate | 2016-06-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 38.